During the European Society for Medical Oncology (ESMO) Congress, Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center presented findings on a novel two-agent treatment that more than doubled progression-free survival compared with single-agent treatment.
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. Research led by Dana-Farber Cancer Institute.
In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma.
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
A UC Davis Health study found 22% of adults and 10% of children who participated in an air-quality study in California’s San Joaquin Valley were breathing detectable levels of pesticides.
The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce plans to make every book in the library of NCCN Guidelines for Patients available in Spanish; with select editions available in additional languages as well.
A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.
Novel treatments, including targeted therapies and antibody drug conjugates, as well as research into improving quality of life for patients with breast cancer, headline studies led by Dana-Farber Cancer Institute and presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
Speakers at an NCCN Oncology Policy Summit discuss the importance of diversity, equity, and inclusion (DEI) as integral to the oncology workforce to improve cancer outcomes, and what to do about backlash.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features compelling data on lung cancer advances presented by MD Anderson researchers at the 2024 World Conference on Lung Cancer.
The Cancer Research Institute (CRI) has appointed Alicia Zhou, PhD, as its new Chief Executive Officer (CEO).
A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surgery and immunotherapy.
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
CRI is co-hosting CICON24 to illuminate pioneering advances in cancer immunotherapy research starting September 8 in National Harbor, MD.
Ruth D. Stephenson, DO, FACOG, gynecologic oncologist at RWJBarnabas Health and Rutgers Cancer Institute, New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, addresses five frequently asked questions about ovarian cancer.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
